Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: A prospective study

Lancet Oncology

Volumn 6, Issue 12, 2005, Pages 945-952

  Vaughan, Thomas L ^a,b   Dong, Linda M ^a,b   Blount, Patricia L ^a   Ayub, Kamran ^c   Odze, Robert D ^d   Sanchez, Carissa A ^a   Rabinovitch, Peter S ^a,b   Reid, Brian J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE; AGED; ANEUPLOIDY; ANTHROPOMETRY; ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CIGARETTE SMOKING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG USE; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK FACTOR; RISK REDUCTION; SEX; TETRAPLOIDY;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SMOKING;

EID: 28044459843     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70431-9     Document Type: Article

References (53)

1. E Bollschweiler E Wolfgarten C Gutschow AH Holscher Demographic variations in the rising incidence of esophageal adenocarcinoma in white males Cancer 92 2001 549-555
2. AP Vizcaino V Moreno R Lambert DM Parkin Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995 Int J Cancer 99 2002 860-868
3. A Kubo DA Corley Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States Am J Gastroenterol 99 2004 582-588
4. A Kubo DA Corley Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States Cancer 95 2002 2096-2102
5. LS Engel WH Chow TL Vaughan et al. Population attributable risks of esophageal and gastric cancers J Natl Cancer Inst 95 2003 1404-1413
6. AP Polednak Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas Int J Cancer 105 2003 98-100
7. RW Phillips RK Wong Barrett's esophagus. Natural history, incidence, etiology, and complications Gastroenterol Clin North Am 20 1991 791-816
8. TG Morales RE Sampliner Barrett's esophagus: Update on screening, surveillance, and treatment Arch Intern Med 159 1999 1411-1416
9. P Sharma EI Sidorenko Are screening and surveillance for Barrett's oesophagus really worthwhile? Gut 54 suppl 1 2005 i27-i32
10. RE Sampliner Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The practice parameters committee of the American College of Gastroenterology Am J Gastroenterol 93 1998 1028-1032
11. AJ Cameron BJ Ott WS Payne The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus N Engl J Med 313 1985 857-859
12. DJ Drewitz RE Sampliner HS Garewal The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4·8 years Am J Gastroenterol 92 1997 212-215
13. W Hameeteman GN Tytgat HJ Houthoff JG van den Tweel Barrett's esophagus: Development of dysplasia and adenocarcinoma Gastroenterology 96 1989 1249-1256
14. M Miros P Kerlin N Walker Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus Gut 32 1991 441-1516
15. JB O'Connor GW Falk JE Richter The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's esophagus registry Am J Gastroenterol 94 1999 2037-2042
16. J Ovaska M Miettinen E Kivilaakso Adenocarcinoma arising in Barrett's esophagus Dig Dis Sci 34 1989 1336-1339
17. CS Robertson JF Mayberry DA Nicholson et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus Br J Surg 75 1988 760-763
18. SJ Spechler AH Robbins HB Rubins et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 87 1984 927-933
19. A van der Burgh J Dees WC Hop M van Blankenstein Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus Gut 39 1996 5-8
20. AP Weston AS Badr RS Hassanein Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma Am J Gastroenterol 94 1999 3413-3419
21. BJ Reid LJ Prevo PC Galipeau et al. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression Am J Gastroenterol 96 2001 2839-2848
22. L Teodori W Gohde M Persiani et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients Cytometry 34 1998 257-263
23. K Dolan AI Morris JR Gosney et al. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus J Gastroenterol Hepatol 18 2003 683-689
24. PS Rabinovitch G Longton PL Blount et al. Predictors of progression in Barrett's esophagus III: Baseline flow cytometric variables Am J Gastroenterol 96 2001 3071-3083
25. TL Vaughan The esophagus In: L Eduardo TER Franco eds. Cancer precursors: Epidemiology, detection, and prevention 2002 Springer New York 96-116
26. JA Tangrea PS Albert E Lanza et al. Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States) Cancer Causes Control 14 2003 403-411
27. SS Husain IL Szabo AS Tamawski NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action Am J Gastroenterol 97 2002 542-553
28. AT Chan EL Giovannucci ES Schernhammer et al. A prospective study of aspirin use and the risk for colorectal adenoma Ann Intern Med 140 2004 157-166
29. JA Baron BF Cole RS Sandler et al. A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 2003 891-899
30. RS Sandler S Halabi JA Baron et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer N Engl J Med 348 2003 883-890
31. T Sturmer RJ Glynn IM Lee et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study Ann Intern Med 128 1998 713-720
32. NR Cook IM Lee JM Gaziano et al. Low-dose aspirin in the primary prevention of cancerA The Women's Health Study: a randomized controlled trial JAMA 294 2005 47-55
33. DC Farrow TL Vaughan PD Hansten et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer Cancer Epidemiol Biomarkers Prev 7 1998 97-102
34. A Gonzalez-Perez LA Garcia Rodriguez R Lopez-Ridaura Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: A meta-analysis BMC Cancer 3 2003 28
35. DA Corley K Kerlikowske R Verma P Buffler Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis Gastroenterology 124 2003 47-56
36. TL Vaughan AR Kristal PL Blount et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus Cancer Epidemiol Biomarkers Prev 11 2002 745-752
37. C Bosetti R Talamini S Franceschi et al. Aspirin use and cancers of the upper aerodigestive tract Br J Cancer 88 2003 672-674
38. NS Buttar KK Wang O Leontovich et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus Gastroenterology 122 2002 1101-1112
39. K Oyama T Fujimura I Ninomiya et al. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats Carcinogenesis 26 2005 565-570
40. MJ Thun NSAIDs and esophageal cancer: Ready for trials but not yet broad clinical application Gastroenterology 124 2003 246-248
41. D Provenzale C Schmitt JB Wong Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk Am J Gastroenterol 94 1999 2043-2053
42. C Hur NS Nishioka GS Gazelle Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus J Natl Cancer Inst 96 2004 316-325
43. C Hur LS Simon GS Gazelle Analysis of aspirin-associated risks in healthy individuals Ann Pharmacother 39 2005 51-57
44. BJ Reid DS Levine G Longton et al. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets Am J Gastroenterol 95 2000 1669-1676
45. RE Rudolph TL Vaughan AR Kristal et al. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus J Natl Cancer Inst 95 2003 750-757
46. BJ Reid PL Blount CE Rubin et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort Gastroenterology 102 1992 1212-1219
47. TL Vaughan DC Farrow PD Hansten et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux Cancer Epidemiol Biomarkers Prev 7 1998 749-756
48. RM Peek Jr Prevention of colorectal cancer through the use of COX-2 selective inhibitors Cancer Chemother Pharmacol 54 suppl 1 2004 S50-S56
49. KT Wilson S Fu KS Ramanujam SJ Meltzer Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas Cancer Res 58 1998 2929-2934
50. HM Kandil G Tanner W Smalley et al. Cyclooxygenase-2 expression in Barrett's esophagus Dig Dis Sci 46 2001 785-789
51. CD Morris GR Armstrong G Bigley et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence Am J Gastroenterol 96 2001 990-996
52. M Lindblad J Lagergren LA Garcia Rodriguez Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer Cancer Epidemiol Biomarkers Prev 14 2005 444-450
53. J Jankowski P Moayyedi Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus J Natl Cancer Inst 96 2004 885-887